BACKGROUND AND OBJECTIVES:Acute respiratory infection (ARI) is among the most common, debilitating and expensive human illnesses. The purpose of this study was to assess ARI-related costs and determine if mindfulness meditation or exercise can add value. METHODS:One hundred and fifty-four adults ≥50 years from Madison, WI for the 2009-10 cold/flu season were randomized to (i) wait-list control (ii) meditation or (iii) moderate intensity exercise. ARI-related costs were assessed through self-reported medication use, number of missed work days and medical visits. Costs per subject were based on cost of generic medications, missed work days ($126.20) and clinic visits ($78.70). Monte Carlo bootstrap methods evaluated reduced costs of ARI episodes. RESULTS: The total cost per subject for the control group was $214 (95% CI: $105-$358), exercise $136 (95% CI: $64-$232) and meditation $65 (95% CI: $34-$104). The majority of cost savings was through a reduction in missed days of work. Exercise had the highest medication costs at $16.60 compared with $5.90 for meditation (P = 0.004) and $7.20 for control (P = 0.046). Combining these cost benefits with the improved outcomes in incidence, duration and severity seen with the Meditation or Exercise for Preventing Acute Respiratory Infection study, meditation and exercise add value for ARI. Compared with control, meditation had the greatest cost benefit. This savings is offset by the cost of the intervention ($450/subject) that would negate the short-term but perhaps not long-term savings. CONCLUSIONS: Meditation and exercise add value to ARI-associated health-related costs with improved outcomes. Further research is needed to confirm results and inform policies on adding value to medical spending.
RCT Entities:
BACKGROUND AND OBJECTIVES: Acute respiratory infection (ARI) is among the most common, debilitating and expensive human illnesses. The purpose of this study was to assess ARI-related costs and determine if mindfulness meditation or exercise can add value. METHODS: One hundred and fifty-four adults ≥50 years from Madison, WI for the 2009-10 cold/flu season were randomized to (i) wait-list control (ii) meditation or (iii) moderate intensity exercise. ARI-related costs were assessed through self-reported medication use, number of missed work days and medical visits. Costs per subject were based on cost of generic medications, missed work days ($126.20) and clinic visits ($78.70). Monte Carlo bootstrap methods evaluated reduced costs of ARI episodes. RESULTS: The total cost per subject for the control group was $214 (95% CI: $105-$358), exercise $136 (95% CI: $64-$232) and meditation $65 (95% CI: $34-$104). The majority of cost savings was through a reduction in missed days of work. Exercise had the highest medication costs at $16.60 compared with $5.90 for meditation (P = 0.004) and $7.20 for control (P = 0.046). Combining these cost benefits with the improved outcomes in incidence, duration and severity seen with the Meditation or Exercise for Preventing Acute Respiratory Infection study, meditation and exercise add value for ARI. Compared with control, meditation had the greatest cost benefit. This savings is offset by the cost of the intervention ($450/subject) that would negate the short-term but perhaps not long-term savings. CONCLUSIONS: Meditation and exercise add value to ARI-associated health-related costs with improved outcomes. Further research is needed to confirm results and inform policies on adding value to medical spending.
Entities:
Keywords:
Complementary and alternative medicine; health economics; physical activity/exercise; prevention; upper respiratory infection/common cold; value.
Authors: Bruce Barrett; Mary S Hayney; Daniel Muller; David Rakel; Ann Ward; Chidi N Obasi; Roger Brown; Zhengjun Zhang; Aleksandra Zgierska; James Gern; Rebecca West; Tola Ewers; Shari Barlow; Michele Gassman; Christopher L Coe Journal: Ann Fam Med Date: 2012 Jul-Aug Impact factor: 5.166
Authors: Bruce Barrett; Maggie Grabow; Cathy Middlecamp; Margaret Mooney; Mary M Checovich; Alexander K Converse; Bob Gillespie; Julia Yates Journal: Sustainability Date: 2016-10-17 Impact factor: 3.251
Authors: Julieta Galante; Claire Friedrich; Anna F Dawson; Marta Modrego-Alarcón; Pia Gebbing; Irene Delgado-Suárez; Radhika Gupta; Lydia Dean; Tim Dalgleish; Ian R White; Peter B Jones Journal: PLoS Med Date: 2021-01-11 Impact factor: 11.069
Authors: Bruce Barrett; Mary S Hayney; Daniel Muller; David Rakel; Roger Brown; Aleksandra E Zgierska; Shari Barlow; Supriya Hayer; Jodi H Barnet; Elisa R Torres; Christopher L Coe Journal: PLoS One Date: 2018-06-22 Impact factor: 3.240